Barclays started coverage on shares of Diplomat Pharmacy (NYSE:DPLO) in a research note released on Thursday, Marketbeat reports. The brokerage issued an overweight rating and a $27.00 price target on the stock.
A number of other research analysts have also weighed in on DPLO. Deutsche Bank raised shares of Diplomat Pharmacy from a hold rating to a buy rating in a research report on Friday, March 2nd. Zacks Investment Research downgraded shares of Diplomat Pharmacy from a buy rating to a hold rating in a report on Wednesday, February 21st. Needham & Company LLC set a $28.00 price objective on shares of Diplomat Pharmacy and gave the stock a buy rating in a report on Tuesday, February 27th. Leerink Swann set a $30.00 price objective on shares of Diplomat Pharmacy and gave the stock a buy rating in a report on Tuesday, February 27th. Finally, Credit Suisse Group upgraded shares of Diplomat Pharmacy from an underperform rating to a neutral rating and set a $28.00 price objective for the company in a report on Thursday, January 25th. Eight research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of $25.38.
Diplomat Pharmacy (NYSE:DPLO) opened at $22.41 on Thursday. The company has a current ratio of 0.97, a quick ratio of 0.66 and a debt-to-equity ratio of 0.70. Diplomat Pharmacy has a 12-month low of $14.00 and a 12-month high of $27.78. The firm has a market cap of $1,659.89, a PE ratio of 25.76 and a beta of 1.32.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Envestnet Asset Management Inc. increased its stake in shares of Diplomat Pharmacy by 27.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 16,655 shares of the company’s stock worth $334,000 after purchasing an additional 3,550 shares in the last quarter. Phocas Financial Corp. increased its stake in shares of Diplomat Pharmacy by 142.9% in the fourth quarter. Phocas Financial Corp. now owns 663,187 shares of the company’s stock worth $13,310,000 after purchasing an additional 390,168 shares in the last quarter. MetLife Investment Advisors LLC purchased a new position in shares of Diplomat Pharmacy in the fourth quarter worth about $448,000. Macquarie Group Ltd. purchased a new position in shares of Diplomat Pharmacy in the fourth quarter worth about $315,000. Finally, Vident Investment Advisory LLC increased its stake in shares of Diplomat Pharmacy by 6.5% in the fourth quarter. Vident Investment Advisory LLC now owns 150,504 shares of the company’s stock worth $3,021,000 after purchasing an additional 9,196 shares in the last quarter. Hedge funds and other institutional investors own 64.62% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Barclays Begins Coverage on Diplomat Pharmacy (DPLO)” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://sportsperspectives.com/2018/03/12/barclays-begins-coverage-on-diplomat-pharmacy-dplo.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.